CG Oncology, Inc. (CGON)

29,98 -0,99 (-3,20%) Börsenschluss: 04:00PM EDT

CG Oncology, Inc.

400 Spectrum Center Drive
Suite 2040
Irvine, CA 92618
United States
(949) 409-3700
https://cgoncology.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 61

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Arthur Kuan	Chairman & CEO	640,97k	N/A	1991
Mr. Ambaw Bellete M.S.	President & COO	1,06M	N/A	1971
Dr. Vijay Kasturi M.D.	Chief Medical Officer	212,24k	N/A	1968
Ms. Corleen M. Roche	CFO & Secretary	N/A	N/A	1967
Ms. Amy Steele	Vice President of Finance, Accounting & Administration	N/A	N/A	N/A
Mr. Swapnil Bhargava Ph.D.	Chief Technical Officer	N/A	N/A	N/A
Mr. Bing Kung	Vice President of Corporate Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Corporate Governance

CG Oncology, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.